Perioperative bleeding in patients undergoing liver transplantation

Anaesthesiol Intensive Ther. 2016;48(1):34-40. doi: 10.5603/AIT.a2015.0020. Epub 2015 Apr 1.

Abstract

Liver transplantation (LT) remains one of the most challenging surgical procedures. For many years uncontrolled bleeding and catastrophic haemorrhages were one of the major causes of perioperative mortality and morbidity. During the past fifty years or so, significant progress in surgical techniques and perioperative management has led to a marked change in transfusion practice over time, where up to 79.6% of LTs in experienced transplant centers are performed without any blood product transfusion. Despite this, perioperative bleeding and transfusion requirements remain potent predictors of patient's mortality, as well as postoperative complications and graft survival. The major impact of blood product transfusion on LT recipient outcomes implies that all patients on waiting lists should be carefully screened for the presence of risk factors of perioperative bleeding. Although multiple predictors of transfusion requirements during LT have been identified, no predictive model validated across centers has been constructed. The most suitable strategies to reduce intraoperative blood loss in this group should be employed on a case-to-case basis. This paper aims to summarize the most up-to-date evidence in the management of haemostasis in LT recipients.

Keywords: bleeding; haemostasis; liver transplantation; perioperative management.

MeSH terms

  • Antifibrinolytic Agents / therapeutic use
  • Blood Loss, Surgical / prevention & control*
  • Blood Transfusion
  • Factor VIIa / therapeutic use
  • Fibrinogen / therapeutic use
  • Humans
  • Liver Transplantation / adverse effects*
  • Postoperative Hemorrhage / therapy*

Substances

  • Antifibrinolytic Agents
  • Fibrinogen
  • Factor VIIa